Clinical Advances in GLP-1 Treatments
Resource Center

According to the American Diabetes Association, more than half of Americans have prediabetes, while more than 30 million adults and children have diabetes. With this increase in the number of patients, a need for more effective and accessible diabetes treatments has also emerged. 

Glucagon-like peptide 1 (GLP-1) receptor agonists are effective at glucose control--with additional benefits including weight control, blood pressure control, cholesterol reduction, and beta-cell function improvement. Now that the ADA recommends GLP-1's as second-line treatment before initiation of insulin, there is an education need for physicians treating patients with T2D. This resource center aims to keep clinicians up-to-date on all the most recent developments in treatment of T2D with GLP-1s.